Overview

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This is a 60-to-72 week multicenter study to evaluate Infergen and Ribavirin in patients with Chronic Hepatitis C Virus after partial response to treatment using peginterferon-alfa and Ribavirin therapy. The study will be conducted at approximately 50 sites across the United States.
Phase:
Phase 4
Details
Lead Sponsor:
Kadmon Pharmaceuticals
Treatments:
Interferon alfacon-1
Interferon-alpha
Ribavirin